Newshero

RECENT NEWS

For Media Inquiries

Alisa Santiesteban, Director of Marketing & Communications
970-926-1277 / Alisa@CanDo-MS.org

Media Kit



    New Data up to 8-Years for Genentech’s Ocrevus (ocrelizumab)

    October 21st, 2021

    Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of Ocrevus® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of a shorter two-hour infusion in minority populations.

    Continue Reading
    Announcing the Second Annual Lokai Run: A Virtual Run for Hope

    September 9th, 2021

    Participants to make their footsteps count by choosing a cause that is meaningful to them.

    Continue Reading
    This September, Celebrate All That Is Possible With Multiple Sclerosis

    August 31st, 2021

    This September, Can Do Multiple Sclerosis honors founder and Olympic ski medalist Jimmie Heuga (1943-2010) with the annual, Can Do Month campaign.

    Continue Reading
    Multiple Sclerosis Summit on Infections and Immunizations in the Era of COVID-19

    August 12th, 2021

    Join NeurologyLive®, the Consortium of Multiple Sclerosis Centers (CMSC), and Can Do MS for a 90-minute virtual summit where experts in immunology, virology, and neurology discuss infections and MS, the persistence of the SARS-CoV-2 virus, the impact of viral variants, the current vaccine landscape, and DMT guidance in a joint forum tailored for healthcare providers as well as patients and caregivers.

    Continue Reading
    MS in Harmony: Helping People Living With Multiple Sclerosis Achieve Mind-Body Harmony Through Music Therapy

    July 6th, 2021

    MS in Harmony: Helping People Living With Multiple Sclerosis Achieve Mind-Body Harmony Through Music Therapy

    Continue Reading
    New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis

    April 26th, 2021

    New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis

    Continue Reading
    Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis

    March 19th, 2021

    TITUSVILLE, N.J.March 19, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

    Continue Reading
    SKI for MS Launches Virtual Vertical Challenge to Help Families Living With MS

    January 22nd, 2021

    SKI for MS, a fundraising ski event benefiting families living with multiple sclerosis (MS), has gone virtual for the 2021 season.

    Continue Reading
    Color Street Donates $300,000 In Support of COVID-19 Response Measures

    January 13th, 2021

    To support their charity partners in the wake of the COVID-19 pandemic, and help offset the expense of measures each organization has implemented to assist their clients, Color Street is donating $10,000 to each of their 30 2018-2020 awareness campaign charity partners. 

    Continue Reading
    This September, show the world how you #ThriveWithMS to inspire others and spread awareness of multiple sclerosis

    August 28th, 2020

    Can Do Multiple Sclerosis, a non-profit that delivers health and wellness education programs for families with MS, launched their annual, online campaign today that encourages people living with MS, as well as their friends and supporters, to share how they thrive with MS during September’s Can Do Month celebration.

    Continue Reading